Skip to main content

Table 3 Evolution of clinical phenotypes of Behçet’s disease in Japan after correction for the follow-up period

From: Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet’s disease: a retrospective observational study

  Group A Pre 2000 (n = 293) Group B 2000–2007 (n = 160) Group C Post 2008 (n = 91) P
Observation time (years) 3.52 ± 1.6 3.25 ± 1.7 3.7 ± 2.2 NS
Age at onset 36.4 ± 11.9 35.8 ± 13.0 37.6 ± 11.4 NS
Gender male, n (%) 121 (41.3) 74 (46.3) 37 (40.7) 0.81
HLA-B51, n (%) 103 (53.4) 47 (50.0) 16 (43.1) 0.031 a
Complete type, n (%) 99 (33.8) 37 (23.1) 16 (17.6) 0.0008
Oral ulcer, n (%) 291 (99.3) 159 (99.4) 88 (96.7) 0.079
Genital ulcer, n (%) 219 (74.7) 112 (70.0) 55 (60.4) 0.0096
Eye involvement, n (%) 184 (62.8) 85 (53.1) 53 (58.2) 0.19
Skin involvement, n (%) 255 (87.0) 137 (85.6) 75 (82.4) 0.28
GI, n (%) 18 (6.1) 19 (11.9) 14 (16.5) 0.0036
CNS, n (%) 20 (6.8) 14 (8.8) 3 (3.3) 0.46
Vascular, n (%) 17 (5.8) 15 (9.4) 3 (3.3) 0.73
Complete type fulfilling, n ISG (%) 99/264 (37.5) 37/135 (27.4) 16/74 (21.6) 0.0037
Complete type w/o GI, n (%) 96/275 (34.9) 35/141 (24.8) 15/77 (19.5) 0.0030
  1. Numbers of patients shown are different from Table 2 because 31 patients were excluded due to ambiguity of the date of phenotype expression. aNot all of the patients were typed for HLA-B51 positivity. GI gastrointestinal, CNS central nervous system, w/o without, NS not significant